Covid 19 Research Clinical Trials by Shray Alag

Janus Kinase Inhibitor (ruxolitinib)

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (2)

	Name (Synonyms)	Correlation
drug3444	SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics Wiki	1.00
drug2916	Placebo Wiki	0.04

Correlated MeSH Terms (5)

	Name (Synonyms)	Correlation
D012120	Respiration Disorders NIH	0.23
D012140	Respiratory Tract Diseases NIH	0.19
D013577	Syndrome NIH	0.09

	Name (Synonyms)	Correlation
D045169	Severe Acute Respiratory Syndrome NIH	0.04
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

	Name (Synonyms)	Correlation

Clinical Trials

Navigate: Correlations HPO

There is one clinical trial.

1 Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection

The COVID-19 pandemic has had a dramatic effect in public health worldwide. In Brazil, there have been more than 2 million confirmed cases and over 75,000 deaths since February 26, 2020. Based on reports of a hyperinflammatory state associated with COVID-19, the use of immunosuppressive drugs may be efficacious in the treatment of this disease. JAK inhibitors have been shown to harness inflammation in a number of different pathologic conditions. The aim of the present study is to evaluate the efficacy and safety of JAK inhibitor ruxolitinib in patients with acute respiratory distress syndrome due to COVID-19.

NCT04477993

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2
SARS-CoV2

Interventions

Drug: Janus Kinase Inhibitor (ruxolitinib)
Other: Placebo

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiration Disorders Respiratory Tract Diseases Syndrome

Primary Outcomes

Measure: A composite outcome of death or ICU admission or mechanical ventilation at day 14.

Time: 14 days

Secondary Outcomes

Measure: A composite outcome of death or ICU admission or mechanical ventilation at day 28

Time: 28 days

Description: ICU admission, mechanical ventilation, death or consent withdrawal

Measure: Time to treatment failure

Time: 28 days

Measure: Overall survival at days 14 and 28

Time: 14 and 28 days

Measure: Cumulative incidence of ICU admission rate at days 14 and 28

Time: 14 and 28 days

Measure: Cumulative incidence of mechanical ventilation at days 14 and 28

Time: 14 and 28 days

Measure: Duration of hospital stay

Time: 28 days

Measure: Duration of ICU stay

Time: 28 days

Measure: Duration of mechanical ventilation

Time: 28 days

Measure: Duration of non-invasive ventilation

Time: 28 days

Measure: Secondary hemophagocytic syndrome rate

Time: 28 days

Measure: Cumulative incidence nosocomial infection rate at days 14 and 28

Time: 14 and 28 days

Measure: Incidence of discontinuation of oxygen supplementation at days 14 and 28

Time: 14 and 28 days

Measure: Rate of grade 1-2 and 3-5 emerging adverse events at day 28

Time: 28 days

Measure: Cumulative dose of methylprednisolone at days 14 and 28

Time: 14 and 28 days

Measure: Change in PaO2/FiO2 ratio from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in interleukin 6 levels [pg/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in d-dimer levels [ng/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in fibrinogen levels [mg/dL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in ferritin levels [ng/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in C reactive protein levels [mg/L] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in alanine aminotransferase [U/L] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in aspartate aminotransferase [U/L] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in creatinine levels [mg/dL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in glucose levels [mg/dL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in hemoglobin levels [g/dL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in platelet count [x10ˆ3/mmˆ3] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in absolute neutrophil count [x10ˆ3/mmˆ3] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in absolute neutrophil count [/mmˆ3] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in absolute lymphocyte count [/mmˆ3] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in prothrombin time ratio from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in partial thromboplastin time ratio from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in bilirubin [mg/dl] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in lactate dehydrogenase [U/L] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in CPK-MB [ng/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in troponin [ng/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in von Willebrand factor antigen level (VWF:Ag) [%] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in von Willebrand factor activity (ristocetin cofactor) [%] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in ADAMTS-13 [%] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in von Willebrand multimeters from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in plasminogen activator inhibitor-1 levels [ng/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in E-selectin levels [ng/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in P-selectin levels [ng/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in endothelin [fmol/mL] from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in circulating microparticles from baseline to days 14 and 28

Time: 14 and 28 days

Measure: Change in thromboelastography from baseline to days 14 and 28

Time: 14 and 28 days

No related HPO nodes (Using clinical trials)

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials

No related HPO nodes (Using clinical trials)

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports MeSH Reports HPO Reports

CovidResearchTrials

Report Sections

See All Reports

Janus Kinase Inhibitor (ruxolitinib)

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (2)

Correlated MeSH Terms (5)

Correlated HPO Terms (0)

Clinical Trials

1 Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection

NCT04477993

Conditions

Interventions

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiration Disorders Respiratory Tract Diseases Syndrome

Primary Outcomes

Secondary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

Report Sections

See All Reports

Janus Kinase Inhibitor (ruxolitinib)

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (2)

Correlated MeSH Terms (5)

Correlated HPO Terms (0)

Clinical Trials

1 Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection Click for details

NCT04477993

Conditions

Interventions

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiration Disorders Respiratory Tract Diseases Syndrome

Primary Outcomes

Secondary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

1 Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection